Your search returned 5 results.

Results
	1.	Linear IgA Disease of the Gingiva Following Nivolumab Therapy. MedStar authors: DeKlotz, Timothy R Khan, Amir PMID: 31246639 Year: 2019 Citation: Journal of Immunotherapy. 42(9):345-347, 2019 Nov/Dec. Institution: MedStar St Mary's Hospital MedStar Washington Hospital Center Department: Otolaryngology Medline publication type: Journal Article Form of publication: Journal Article All authors: DeKlotz T, Gibney GT, Jonna S, Khan A, Lakshmanan S, Lanasa D, Liu SV, Neiders M DOI: https://dx.doi.org/10.1097/CJI.0000000000000288 Add to cart (remove)
	2.	A case of checkpoint inhibitor-induced celiac disease. MedStar authors: Alsaadi, Dana PMID: 31383006 Year: 2019 Citation: Journal for Immunotherapy of Cancer. 7(1):203, 2019 08 05. Institution: MedStar Washington Hospital Center Department: Medicine/Internal Medicine Medline publication type: Journal Article Form of publication: Journal Article All authors: Alsaadi D, Atkins MB, Charabaty A, Shah NJ DOI: https://dx.doi.org/10.1186/s40425-019-0694-x Add to cart (remove)
	3.	Clinical Activity of Nivolumab for Human Papilloma Virus-Related Juvenile-Onset Recurrent Respiratory Papillomatosis. MedStar authors: Grant, Nazaneen N PMID: 30842242 Year: 2019 Citation: Oncologist. 24(6):829-835, 2019 06. Institution: MedStar Washington Hospital Center Department: Otolaryngology Medline publication type: Journal Article Form of publication: Journal Article All authors: Ahmad MU, Creelan BC, Grant NN, Kaszuba FJ, Khalil FK, Ozdemirli M, Subramaniam DS, Welsh AW DOI: https://dx.doi.org/10.1634/theoncologist.2018-0505 Add to cart (remove)
	4.	Pseudo-Wellens' Syndrome Temporally Associated With Immune Check Point Inhibitors Use. MedStar authors: Al-Shbool, Ghassan Muhailan, Mohamad PMID: 31395282 Year: 2020 Citation: American Journal of the Medical Sciences. 359(1):e1-e2, 2020 01. Institution: MedStar Washington Hospital Center Department: Medicine/Internal Medicine Medline publication type: Letter Form of publication: Journal Article All authors: Al-Shbool G, Muhailan M DOI: https://dx.doi.org/10.1016/j.amjms.2019.07.006 Add to cart (remove)
	5.	Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. MedStar authors: Chitalia, Ami Gallagher, Christopher Schlam, Ilana Swain, Sandra M Tiwari, Shruti PMID: 38538574 Year: 2024 Citation: Nature communications . 15(1):2691, 2024 Mar 27. Institution: Washington Cancer Institute Department: Associate Dean for Research Development MedStar Health Medline publication type: Clinical Trial, Phase II Journal Article Randomized Controlled Trial Form of publication: Journal Article All authors: Lynce F, Mainor C, Donahue RN, Geng X, Jones G, Schlam I, Wang H, Toney NJ, Jochems C, Schlom J, Zeck J, Gallagher C, Nanda R, Graham D, Stringer-Reasor EM, Denduluri N, Collins J, Chitalia A, Tiwari S, Nunes R, Kaltman R, Khoury K, Gatti-Mays M, Tarantino P, Tolaney SM, Swain SM, Pohlmann P, Parsons HA, Isaacs C DOI: https://dx.doi.org/10.1038/s41467-024-46961-x Add to cart (remove)

Powered by Koha